Company profile: Eton Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of proprietary formulations of approved molecules and pharmaceutical products to fulfill unmet patient needs. Develops and commercializes a diversified pipeline of around eight candidates in various stages. Receives milestone payments and royalties on commercial sales from seven products it developed and submitted regulatory applications for to the FDA.
Products and services
- Proprietary Formulations Development: Eton Pharmaceuticals develops proprietary formulations of approved molecules to offer improvements for patients and physicians, custom-engineered
- Royalty Products: Eton Pharmaceuticals receives milestone payments or royalties on commercial sales from seven pharmaceutical products it engineered and submitted regulatory applications for to the FDA, FDA-submitted
- Diversified Pipeline Development: Eton Pharmaceuticals architects and commercializes a diversified pipeline of around eight product candidates in various stages of development addressing unmet patient needs, multi-stage
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Eton Pharmaceuticals
Paloma Pharmaceuticals
HQ: United States
Website
- Description: Provider of early-stage drug development focusing on pathologies showing an aberrant up-regulation of the PI3K/Akt/mTOR pathway, including cancer, ocular diseases (macular degeneration and diabetic retinopathy), arthritis, fibrotic diseases (renal and pulmonary fibrosis), and CNS (epilepsy and neurodegenerative).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Paloma Pharmaceuticals company profile →
Ablynx
HQ: Belgium
Website
- Description: Provider of a proprietary Nanobody® technology platform for the discovery and development of therapeutic nanobodies—small single-domain antibody fragments—targeting serious human diseases including inflammation, haematology, oncology and pulmonary disease, with approximately 25 projects in the pipeline.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ablynx company profile →
Celgene
HQ: United States
Website
- Description: Provider of innovative biopharmaceutical therapies focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory-related diseases, serving patients with limited treatment options, with hundreds of clinical trials at major medical centers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Celgene company profile →
Antibe Therapeutics
HQ: Canada
Website
- Description: Provider of novel anti-inflammatory drugs that improve existing, proven therapies, targeting diseases characterized by inflammation, pain, and vascular dysfunction. Offers a proprietary hydrogen sulfide platform; pipeline includes Otenaproxesul for acute pain with demonstrated gastrointestinal safety and efficacy in chronic pain, ATB-352 for specialized pain, and a program for mild-to-moderate inflammatory bowel disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Antibe Therapeutics company profile →
Ascendis Pharma
HQ: United States
Website
- Description: Provider of the TransCon prodrug technology platform, which transiently conjugates an inert carrier to a parent drug for systemic or localized release, and a pipeline of investigational therapies: TransCon hGH for growth hormone deficiency, TransCon PTH for hypoparathyroidism, TransCon CNP for achondroplasia, and oncology candidates TransCon TLR7/8 Agonist and TransCon IL-2 β/γ.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ascendis Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Eton Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Eton Pharmaceuticals
2.2 - Growth funds investing in similar companies to Eton Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Eton Pharmaceuticals
4.2 - Public trading comparable groups for Eton Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →